Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History VSTM

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics VSTM

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

Verastem Inc

VSTM
Current price
5.16 USD -0.01 USD (-0.19%)
Last closed 5.11 USD
ISIN US92337C2035
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 283 537 856 USD
Yield for 12 month +55.42 %
1Y
3Y
5Y
10Y
15Y
VSTM
21.11.2021 - 28.11.2021

Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts. Address: 117 Kendrick Street, Needham, MA, United States, 02494

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

15.25 USD

P/E Ratio

Dividend Yield

Financials VSTM

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures VSTM

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

+10 000 000 USD

Last Year

Current Quarter

Last Quarter

-9 976 000 USD

Current Year

+9 974 000 USD

Last Year

-62 000 USD

Current Quarter

Last Quarter

-9 988 000 USD
EBITDA -131 041 000 USD
Operating Margin TTM -1 310.71 %
Price to Earnings
Return On Assets TTM -64.19 %
PEG Ratio -1.89
Return On Equity TTM -2 159.52 %
Wall Street Target Price 15.25 USD
Revenue TTM 10 000 000 USD
Book Value -0.63 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY -100.00 %
Dividend Yield
Gross Profit TTM 10 000 000 USD
Earnings per share -3.36 USD
Diluted Eps TTM -3.36 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY
Profit Margin

Stock Valuation VSTM

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 22.79
Price Sales TTM 28.35
Enterprise Value EBITDA -0.19
Price Book MRQ 6.04

Technical Indicators VSTM

For 52 Weeks

2.10 USD 9.10 USD
50 Day MA 6.14 USD
Shares Short Prior Month 12 182 979
200 Day MA 5.32 USD
Short Ratio 5.15
Shares Short 15 748 949
Short Percent 22.27 %